Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia. According to GlobalData, Phase II drugs for Paraplegia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Melpida LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Melpida overview

Melpida is under development for the treatment of spastic paraplegia type 50 (SPG50). The therapeutic candidate comprises recombinant adeno-associated virus (serotype 9) encoding a codon optimized human AP4M1 transgene (hAP4M1opt). It is administered through intrathecal route.

Elpida Therapeutics overview

Elpida Therapeutics is a biotechnology research company that delivers gene therapies to patients and offers toxicology plasmid, clinical trials, cell culture and cell therapy products. The company is headquartered in Los Angeles, California, the US.

For a complete picture of Melpida’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.